Pharmacological analysis of integrin function: Inhibition of vascular stenosis and identification of a novel antiplatelet substance

Folia Pharmacologica Japonica

Volumn 115, Issue 3, 2000, Pages 143-150

  Matsuno, Hiroyuki ^a  

^a GIFU UNIVERSITY   (Japan)

Author keywords

HSP; Integrin; Platelets; Vascular stenosis

Indexed keywords

ANTITHROMBOCYTIC AGENT; FIBRINOGEN RECEPTOR ANTAGONIST;

ARTERY INTIMA PROLIFERATION; CONFERENCE PAPER; CORONARY ARTERY OBSTRUCTION; DRUG MECHANISM; DRUG POTENCY; HUMAN; THROMBOCYTE AGGREGATION INHIBITION;

EID: 0034076057     PISSN: 00155691     EISSN: None     Source Type: Journal    
DOI: 10.1254/fpj.115.143     Document Type: Conference Paper

References (34)

1. Ferns GA, Raines EW, Sprugel KH, Motani AS, Reidy MA and Ross R: Inhibition of neointimal smooth muscle accumulation after angioplasty by anantibody to PDGF. Science 253(5024), 1129-1132 (1991)
2. Sporn MB, Roberts AB, Wakefield LM and Assoian RK: Transforming growth factor-beta: biological function and chemical structure. Science 233(4763), 532-534 (1986)
3. Madtes DK, Raines EW, Sakariassen KS, Assoian RK, Sporn MB, Bell GI and Ross R: Induction of transforming growth factor-alpha in activated human alveolar macrophages. Cell 53(2), 285-293 (1988)
4. Wilentz JR, Sanborn TA, Haudenschild CC, Valeri CR, Ryan TJ and Faxon DP: Platelet accumulation in experimental angioplasty: time course and relation to vascular injury. Circulation 75(3), 636-642 (1987)
5. Badimon L, Badimon JJ, Galvez A, Chesebro JH and Fuster V: Influence of arterial damage and wall shear rate on platelet deposition. Ex vivo study in a swine model. Arteriosclerosis 6(3), 312-320 (1986)
6. Weiss HJ, Hawiger J, Ruggeri ZM, Turitto VT, Thiagarajan P and Hoffmann T: Fibrinogen-independent platelet adhesion and thrombus formation on subendothelium mediated by glycoprotein IIb-IIIa complex at high shear rate. J Clin Invest 83(1), 288-297 (1989)
7. Moore S, Friedman RJ, Singal DP, Gauldie J, Blajchman MA and Roberts RS: Inhibition of injury induced thromboatherosclerotic lesions by anti-platelet serum in rabbits. Thromb Haemost 35 (1), 70-81 (1976)
8. Friedman RJ, Stemerman MB, Wenz B, Moore S, Gauldie J, Gent M, Tiell ML and Spaet H: The effect of thrombocytopenia on experimental arteriosclerotic lesion formation in rabbits. Smooth muscle cell proliferation and re-endothelialization. J Clin Invest 60(5), 1191-1201 (1977)
9. Liu MW, Roubin GS, Robinson KA, Black AJ, Hearn JA, Siegel RJ and King SB 3d: Trapidil in preventing restenosis after balloon angioplasty in the atherosclerotic rabbit. Circulation 81(3), 1089-1093 (1990)
10. Powell JS, Clozel JP, Muller RK, Kuhn H, Hefti F. Hosang M and Baumgartner HR: Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 245 (4914), 186-188 (1989)
11. Shiota N, Fukamizu A, Takai S, Okunishi H, Murakami K and Miyazaki M: Activation of angiotensin II-forming chymase in the cardiomyopathic hamster heart. J Hypertens 15(4), 431-440 (1997)
12. Matsuno H, Stassen JM, Hoylaerts MF, Vermylen J and Deckmyn H: Fast and reproducible vascular neointima formation in the hamster carotid artery: effects of trapidil and captopril. Thromb Haemost 74(6), 1591-1596 (1995)
13. Bendeck MP, Zempo N, Clowes AW, Galardy RE and Reidy MA: Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ Res 75(3), 539-545 (1994)
14. Matsuno H, Stassen JM, Vermylen J and Deckmyn H: Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation. Circulation 90(5), 2203-2206 (1994)
15. Matsuno H, Stassen JM, Moons L, Vermylen J and Hoylaerts MF: Neointima formation in injured hamster carotid artery is effectively prevented by the combination G4120 and quinapril. Thromb Haemost 76(2), 263-269 (1996)
16. Kaida T, Matsuno H, Niwa M, Kozawa O, Miyata H and Uematsu T: Antiplatelet effect of FK633, a platelet glycoprotein IIb/IIIa antagonist, on thrombus formation and vascular patency after thrombolysis in the injured hamster carotid artery. Thromb Haemost 77(3), 562-567 (1997)
17. Matsuno H, Kozawa O, Niwa M, Kaida T, Hayashi H and Uematsu T: GR144053, a fibrinogen receptor antagonist, enhances the suppression of neointima formation by losartan, an angiotensin II receptor antagonist, in the injured carotid artery of hamster. Br J Pharmacol 122(6), 1099-1104 (1997)
18. Matsuno H, Kozawa O, Niwa M, Ito T, Tanabe K, Nishida M, Hayashi H and Uematsu T: Effect of GR144053, a fibrinogen-receptor antagonist, on thrombus formation and vascular patency after thrombolysis by tPA in the injured carotid artery of the hamster. J Cardiovasc Pharmacol 32(2), 191-197 (1998)
19. Ito T, Matsuno H, Kozawa O, Niwa M, Sakai N and Uematsu T: Comparison of the antithrombotic effects and bleeding risk of fractionated aurin tricarboxylic acid and the GPIIb/IIIa antagonist GR 144053 in a hamster model of stenosis. Thromb Res 95(1), 49-61 (1999)
20. Kawasaki T, Kaku S, Kohinata T, Sakai Y, Taniuchi Y, Kawamura K, Yano S, Takenaka T and Fujimura Y: Inhibition by aurintricarboxylic acid of von Willebrand factor binding to platelet GPIb, platelet retention, and thrombus formation in vivo. Am J Hematol 47(1), 6-15 (1994)
21. Matsuno H, Kozawa O, Niwa M and Uematsu T: Inhibition of von Willebrand factor binding to platelet GP Ib by a fractionated aurintricarboxylic acid prevents restenosis after vascular injury in hamster carotid artery. Circulation 96(4), 1299-12304 (1997)
22. Matsuno H, Kozawa O, Niwa M, Tanabe K, Ichimaru K, Takiguchi Y, Yokota M, Hayashi H and Uematsu T: Multiple inhibition of platelet activation by aurintricarboxylic acid prevents vascular stenosis after endothelial injury in hamster carotid artery. Thromb Haemost 79(4), 865-871 (1998)
23. Matsuno H, Kozawa O, Niwa M, Usui A, Ito H, Uematsu T and Kato K: A heat shock-related protein, p20, plays an inhibitory role in platelet activation. FEBS Lett 429, 327-329 (1998)
24. Dong JF, Sae-Tung G and Lopez JA: Role of glycoprotein V in the formation of the platelet high-affinity thrombin-binding site. Blood 89(12), 4355-4363 (1997)
25. Fredrickson BJ, Dong JF, Mclntire LV and Lopez JA: Shear-dependent rolling on von Willebrand factor of mammalian cells expressing the platelet glycoprotein Ib-IX-V complex. Blood 92(10), 3684-3693 (1998)
26. Topol EJ, Ferguson JJ, Weisman HF, Tcheng JE, Ellis SG, Kleiman NS, Ivanhoe RJ, Wang AL, Miller DP, Anderson KM, et al: Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. JAMA 278(6), 479-484 (1997)
27. Anonymous: Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC. N Engl J Med 330(14), 956-961 (1994)
28. Anonymous: Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med 336(24), 1689-1696 (1997)
29. Hamm CW, Heeschen C, Goldmann B, Vahanian A, Adgey J, Miguel CM, Rutsch W, Berger J, Kootstra J and Simoons ML: Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. N Engl J Med 340 (21), 1623-1629 (1999)
30. Anonymous: Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. Circulation 96(5), 1445-1453 (1997)
31. Anonymous: A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. N Engl J Med 338 (21), 1498-1505 (1998)
32. Anonymous: International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network. Circulation 97 (24), 2386-2395 (1998)
33. Murata M, Fukuyama M, Satoh K, Fujimura Y, Yoshioka A, Takahashi H, Handa M, Kawai Y, Watanabe K and Ikeda Y: Low shear stress can initiate von Willebrand factor-dependent platelet aggregation in patients with type IIB and platelet-type von Willebrand disease. J Clin Invest 92(3), 1555-1558 (1993)
34. Iijima K, Murata M, Nakamura K, Kitaguchi T, Handa M, Watanabe K, Fujimura Y, Yoshioka A and Ikeda Y: High shear stress attenuates agonist-induced, glycoprotein lib IIb/IIIa-mediated platelet aggregation when von Willebrand factor binding to glycoprotein Ib/IX is blocked. Biochem Biophys Res Commun 233(3), 796-800 (1997)